eFFECTOR Therapeutics, Inc. (EFTR) News

eFFECTOR Therapeutics, Inc. (EFTR): $1.69

-0.01 (-0.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EFTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 433

in industry

Filter EFTR News Items

EFTR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EFTR News Highlights

  • EFTR's 30 day story count now stands at 4.
  • Over the past 7 days, the trend for EFTR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about EFTR are BIO, MS and ROOT.

Latest EFTR News From Around the Web

Below are the latest news stories about eFFECTOR Therapeutics Inc that investors may wish to consider to help them evaluate EFTR as an investment opportunity.

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company’s board of directors. Concurrent with Ms. Harrington-Smith’s appointment, Jonathan Root, M.D., has resigned from the company’s board of direct

Yahoo | February 16, 2022

These 2 Stocks Could Be Bought Out, Says Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth a total of $2.5 trillion, more than 25% higher than the previous record, 2015’s $1.96 trillion.

Michael Marcus on TipRanks | February 15, 2022

2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth

Yahoo | February 15, 2022

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference. Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will provide an overview of the Company’s clinical developm

Yahoo | February 9, 2022

eFFECTOR Therapeutics provides pipeline update; inks up to $50M investment contract

eFFECTOR Therapeutics (EFTR) announced pipeline updates and an investment agreement with Lincoln Park Capital for a commitment of up to $50M over 36 months.The company said that a

Seeking Alpha | January 24, 2022

eFFECTOR Therapeutics Provides Pipeline and Business Updates

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient population, representing additional $5 billion U.S. market opportunity First patients dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and in combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer Company en

Yahoo | January 24, 2022

Brokerages Expect eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Will Post Earnings of -$0.25 Per Share

Wall Street analysts forecast that eFFECTOR Therapeutics Inc (NASDAQ:EFTR) will announce earnings per share of ($0.25) for the current quarter, Zacks reports. Zero analysts have made estimates for eFFECTOR Therapeutics earnings. The firm is scheduled to issue its next earnings results on Monday, February 14th. On average, analysts expect that eFFECTOR Therapeutics will report full-year []

Transcript Daily | December 15, 2021

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Director Jonathan D. Root Sells 8,113 Shares of Stock

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Director Jonathan D. Root sold 8,113 shares of the companys stock in a transaction that occurred on Thursday, December 2nd. The shares were sold at an average price of $5.68, for a total transaction of $46,081.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which []

Transcript Daily | December 7, 2021

Presidio Management Group X. Ll Sells 19,245 Shares of eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) major shareholder Presidio Management Group X. Ll sold 19,245 shares of the firms stock in a transaction on Wednesday, December 1st. The stock was sold at an average price of $6.44, for a total value of $123,937.80. The transaction was disclosed in a document filed with the SEC, which is accessible []

Dakota Financial News | December 3, 2021

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Major Shareholder Sells $110,104.60 in Stock

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) major shareholder Presidio Management Group X. Ll sold 14,879 shares of the firm’s stock in a transaction that occurred on Tuesday, November 23rd. The stock was sold at an average price of $7.40, for a total transaction of $110,104.60. The sale was disclosed in a legal filing with the SEC, which […]

Transcript Daily | November 29, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5578 seconds.